½ÃÀ庸°í¼­
»óǰÄÚµå
1349857

ÇãÇ÷Àç°ü·ù ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : Ä¡·á¹ýº°, »óÇØº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ±Ô¸ð, Á¡À¯À², Àü¸Á, ±âȸ ºÐ¼®(2023-2030³â)

Ischemia Reperfusion Injury Therapeutics Market, By Treatment, By Injury, By End User, and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)-Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÇãÇ÷Àç°ü·ù ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 20¾ï 6,000¸¸ ´Þ·¯·Î ÃßÁ¤¡¤¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß(2023-2030³â) CAGRÀº 6%·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ´ë»ó ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁسâ 2022 2023³â ½ÃÀå ±Ô¸ð 20¾ï 6,000¸¸ ´Þ·¯
°ú°Å µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030
¿¹Ãø ±â°£ 2023-2030³â CAGR : 6.00% 2030³â °¡Ä¡ ¿¹Ãø 30¾ï 9,000¸¸ ´Þ·¯
Ischemia Reperfusion Injury Therapeutics Market-IMG1

ÇãÇ÷ Àç°ü·ù Àå¾Ö(IRI)´Â Àç»ê¼Ò Àå¾Ö¶ó°íµµ Çϸç, »ê¼Ò ºÎÁ· ±â°£(ÇãÇ÷) ÈÄ Ç÷¾× °ø±ÞÀÌ Á¶Á÷À¸·Î µ¹¾Æ°¥ ¶§(Àç°ü·ù) ¹ß»ýÇÏ´Â Á¶Á÷ ¼Õ»óÀÔ´Ï´Ù. ÇãÇ÷¼º ¼Õ»óÀÇ Áõ»óÀ¸·Î´Â ¼­¸Æ, µÎÅë, °íÇ÷¾Ð, °æ·Ã µîÀÌ ÀÖ½À´Ï´Ù. ÇãÇ÷ Àç°ü·ù Àå¾Ö´Â ½É±Ù µ¿¸é, ±Þ¼º ½ÉºÎÀü, ³ú ±â´É Àå¾Ö, ¼ÒÈ­°ü ±â´É Àå¾Ö, Àü½Å ¿°Áõ ¹ÝÀÀ ÁõÈıº, ´Ù¹ß¼º Àå±â ºÎÀü ÁõÈıº°ú °°Àº ½É°¢ÇÑ ÀÓ»ó Áõ»óÀ» µ¿¹ÝÇÕ´Ï´Ù. ÇãÇ÷¼º Àç°ü·ù Àå¾Ö´Â Àǻ翡°Ô Áß¿äÇÑ Ä¡·á °úÁ¦¸¦ Á¦±âÇÏ´Â ½É°¢ÇÑ º´¸® Çö»óÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ

Àç°ü·ù Àå¾Ö¸¦ ¾Î°í Àִ ȯÀÚ Ä¡·á¸¦ À§ÇØ ÁÖ¿ä ½ÃÀå Âü¿©ÀÚµéÀÇ ¿¬±¸°³¹ß Ȱµ¿ÀÌ È°¹ßÇØÁü¿¡ µû¶ó ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 5¿ù 31ÀÏ, Á¦¾àȸ»ç GNT Pharma´Â Nelonemdaz°¡ ÀÓ»ó 1»ó ½ÃÇè ÁßÀ̶ó°í º¸°íÇß½À´Ï´Ù. ³Ú·Î³Û´ÙÁî(Neu2000)´Â ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß, ¿Ü»ó¼º ³ú¼Õ»ó, ¿Ü»ó¼º ô¼ö¼Õ»ó, ±Þ¼º ½É±Ù°æ»ö(AMI) ¹× È­»ó, ³ú°æ»ö Ä¡·áÁ¦·Î °³¹ßµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ 2021³â 9¿ù, Á¦¾à»ç Áö¿£Æ¼ÆÄ¸¶´Â Çѱ¹ ½ÄǰÀǾàǰ¾ÈÀüó(MFDS)°¡ ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ³×·Î³ª¸¿´ÙÁîÀÇ ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ÀÓ»ó 3»ó ½ÃÇè(RODIN ½ÃÇè)ÀÇ ÀÓ»ó½ÃÇè°èȹ(IND)À» ½ÂÀÎÇß´Ù°í ¹àÇû½À´Ï´Ù. À̹ø IND ½ÂÀÎÀº GNTÁ¦¾àÀÌ ÀÌÀü¿¡ ¼öÇàÇÑ ÀÓ»ó 2»ó ½ÃÇèÀÇ ÁÁÀº °á°ú¸¦ ¹ÙÅÁÀ¸·Î ÀÌ·ç¾îÁ³½À´Ï´Ù. À̹ø ÀÓ»ó 3»ó °á°ú´Â ±Þ¼º ÇãÇ÷¼º ³úÁ¹ÁßÀÇ È¿°úÀûÀÎ Ä¡·áÁ¦·Î¼­ ³×·Î³ª¸¿´ÙÁîÀÇ Ä¡·á °¡´É¼ºÀ» ÀÔÁõÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ»ÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

º» ½ÃÇèÀÇ ÁÖ¿ä Æ¯Â¡

º» ½ÃÇèÀÇ ÁÖ¿ä Æ¯Â¡
  • ÀÌ º¸°í¼­´Â ¼¼°è ÇãÇ÷¼º Àç°ü·ù Àå¾Ö Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®Çϰí 2022³âÀ» ±âÁØ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2023-2030³â) ½ÃÀå ±Ô¸ð¿Í CAGRÀ» Á¦½ÃÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®ÀÇ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ÆÄ¾ÇÇϰí ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÑ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °í·Á »çÇ×µµ Á¦°øÇÕ´Ï´Ù.
  • ¼¼°è ÇãÇ÷¼º Àç°ü·ù Àå¾Ö Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • Á¶»ç ´ë»ó ÁÖ¿ä ±â¾÷À¸·Î´Â Revive Therapeutics Ltd. Opsona Therapeutics Limited, PledPharma AB, Prothix BV, Prothix BV, Proteo, Inc. BioTherapeutics Inc., Zealand Pharma A/S, Antipodean Pharmaceuticals, Inc. Pharma GmbH, Biomedica Management Corporation, Ensemble Therapeutics Corporation, Gilead Sciences, Inc.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è ÀÇ·á ¿µ»ó Àåºñ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ÇãÇ÷¼º Àç°ü·ù Àå¾Ö Ä¡·áÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå °³¿ä

  • ¸®Æ÷Æ® °³¿ä
    • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ±âȸ
  • ¿µÇ⠺м®
  • ÃÖ±Ù Á¦Ç° ÆÇ¸Å
  • ¿ªÇÐ
  • ÇÕº´, Àμö, Á¦ÈÞ
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • ÁÖ¿ä ¹ßÀü
  • PEST ºÐ¼®
  • ÆÄÆ®³Ê½Ê ½Ã³ª¸®¿À
  • ºê·£µå¿Í °¡°Ý ºÐ¼®
  • À¯Åë¾÷ü »óȲ
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • ±â¼úÀû Áøº¸
  • ÁÖ¿ä ¹ßÀü
  • ½ÃÀå µ¿Çâ
  • ¸ÅÃ⺰ÀÇ ÁÖ¿ä ±â¾÷

Á¦4Àå ¼¼°èÀÇ ÇãÇ÷Àç°ü·ù ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : COVID-19 ¿µÇ⠺м®

  • °æÁ¦Àû ¿µÇâ
  • COVID-19 ¿ªÇÐ
  • ¼ö±Þ¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ÇãÇ÷Àç°ü·ù ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : Ä¡·á¹ýº°, 2018-2030³â

  • ¾à¹° ¿ä¹ý
  • ¾à¿ë °¡½º
  • ±âŸ(ºñŸ¹Î ¿ä¹ý µî)

Á¦6Àå ¼¼°èÀÇ ÇãÇ÷Àç°ü·ù ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : »óÇØ À¯Çüº°, 2018-2030³â

  • ½ÉÀå ¼Õ»ó
  • ½ÅÀå ¼Õ»ó
  • Àå¼Õ»ó
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ÇãÇ÷Àç°ü·ù ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, 2018-2030³â

  • º´¿ø
  • Àü¹® Ŭ¸®´Ð
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ(Çмú¿¬±¸±â°ü µî)

Á¦8Àå ¼¼°èÀÇ ÇãÇ÷Àç°ü·ù ¼Õ»ó Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº°, 2018-2030³â

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • GCC
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • Revive Therapeutics Ltd.
  • Faraday Pharmaceuticals
  • Abiomed
  • Omeros Corporation
  • Pharming Group N.V.
  • Nyken B.V.
  • Orexo AB
  • Opsona Therapeutics Limited
  • PledPharma AB
  • Prothix BV
  • Proteo, Inc.
  • Amyndas Pharmaceuticals LLC
  • Prolong Pharmaceuticals
  • Stealth BioTherapeutics Inc.
  • Zealand Pharma A/S
  • Antipodean Pharmaceuticals, Inc.
  • Bayer AG
  • Angion Biomedica Corp.
  • Bolder Biotechnology, Inc.
  • Curatis Pharma GmbH
  • Biomedica Management Corporation
  • Ensemble Therapeutics Corporation
  • Gilead Sciences, Inc.
  • Erimos Pharmaceuticals, LLC.

Á¦10Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç ¼Ò°³
KSA 23.10.05

The global ischemia reperfusion injury therapeutics market is estimated to be valued at US$ 2.06 Bn in 2023 and is expected to exhibit a CAGR of 6% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 2.06 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 6.00% 2030 Value Projection: US$ 3.09 Bn
Ischemia Reperfusion Injury Therapeutics Market - IMG1

Ischemia reperfusion injury (IRI), also known as reoxygenation injury, is tissue damage that arises when blood supply returns to the tissue (reperfusion) after a period of lack of oxygen (ischemia). The symptoms of an ischemia injury include bradycardia, headache, hypertension, and seizures. Ischemia-reperfusion injury is associated with serious clinical manifestations, including myocardial hibernation, acute heart failure, cerebral dysfunction, gastrointestinal dysfunction, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome. Ischemia-reperfusion injury is a critical medical condition that poses an important therapeutic challenge for physicians.

Market Dynamics

Increasing number of research and development activities by the key market players for the treatment of patients suffering from reperfusion injury is expected to drive the growth of market over the forecast period. For instance, on May 31, 2022, GNT Pharma, a pharmaceutical company,reported that Nelonemdaz is under clinical for phase I clinical trial. Nelonemdaz (Neu2000) is under development for the treatment of acute ischemic stroke, traumatic brain injury, traumatic spinal cord injury, acute myocardial infarction (AMI) and burn injury, cerebral infarction.

Furthermore, in September 2021, GNT Pharma, a pharmaceutical company, reported that the Korea Ministry of Food and Drug Safety (MFDS) had approved the Investigational New Drug Application (IND) for a phase III study of nelonemdaz for acute ischemic stroke patients (RODIN trial). The IND approval for a more extensive phase III trial is based on the encouraging results of GNT Pharma's earlier phase II trials. The outcomes of this phase III study will be instrumental in documenting the therapeutic potential of nelonemdaz as an effective treatment for acute ischemic stroke.

Key features of the study:

  • This report provides an in-depth analysis of the global ischemia reperfusion injury therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global ischemia reperfusion injury therapeutics market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Revive Therapeutics Ltd., Faraday Pharmaceuticals, Abiomed, Omeros Corporation, Pharming Group N.V., Nyken B.V., Orexo AB, Opsona Therapeutics Limited, PledPharma AB, Prothix BV, Proteo, Inc., Amyndas Pharmaceuticals LLC, Prolong Pharmaceuticals, Stealth BioTherapeutics Inc., Zealand Pharma A/S, Antipodean Pharmaceuticals, Inc., Bayer AG, Angion Biomedica Corp., Bolder Biotechnology, Inc., Curatis Pharma GmbH, Biomedica Management Corporation, Ensemble Therapeutics Corporation, Gilead Sciences, Inc., and Erimos Pharmaceuticals, LLC.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global medical imaging equipment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ischemia reperfusion injury therapeutics market

Detailed Segmentation:

  • Global Ischemia Reperfusion Injury Therapeutics Market, By Treatment:
    • Drug Therapy
    • Medicated Gas
    • Others (Vitamin Therapy and among Others)
  • Global Ischemia Reperfusion Injury Therapeutics Market, By Injury Type:
    • Heart Injury
    • Kidney Injury
    • Intestine Injury
    • Other Injury (Brain Injuries and Among Others)
  • Global Ischemia Reperfusion Injury Therapeutics Market, By End user:
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Others(Academic and Research Institutes and among Others)
  • Global Ischemia Reperfusion Injury Therapeutics Market, By Region:
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Revive Therapeutics Ltd.
    • Faraday Pharmaceuticals
    • Abiomed
    • Omeros Corporation
    • Pharming Group N.V.
    • Nyken B.V.
    • Orexo AB
    • Opsona Therapeutics Limited
    • PledPharma AB
    • Prothix BV
    • Proteo, Inc.
    • Amyndas Pharmaceuticals LLC
    • Prolong Pharmaceuticals
    • Stealth BioTherapeutics Inc.
    • Zealand Pharma A/S
    • Antipodean Pharmaceuticals, Inc.
    • Bayer AG
    • Angion Biomedica Corp.
    • Bolder Biotechnology, Inc.
    • Curatis Pharma GmbH
    • Biomedica Management Corporation
    • Ensemble Therapeutics Corporation
    • Gilead Sciences, Inc.
    • Erimos Pharmaceuticals, LLC.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Treatment
    • Market Snapshot, By Injury Type
    • Market Snapshot, By End user
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Product Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis
  • Partnership Scenario
  • Brand and Pricing Analysis
  • Distributors Landscape
  • Porters Analysis
  • Technological Advancements
  • Key Developments
  • Market Trend
  • Top Market Players by Revenue

4. Global Ischemia Reperfusion Injury Therapeutics Market- COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Ischemia Reperfusion Injury Therapeutics Market, By Treatment, 2018-2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Drug Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
    • Segment Trends
  • Medicated Gas
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
    • Segment Trends
  • Others (Vitamin Therapy and among Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
    • Segment Trends

6. Global Ischemia Reperfusion Injury Therapeutics Market, By Injury Type, 2018-2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Heart Injury
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
    • Segment Trends
  • Kidney Injury
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
    • Segment Trends
  • Intestine Injury
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
    • Segment Trends
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
    • Segment Trends

7. Global Ischemia Reperfusion Injury Therapeutics Market, By End user, 2018-2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
  • Others (Academic and Research Institutes and among Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

8. Global Ischemia Reperfusion Injury Therapeutics Market, By Region, 2018-2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2018-2030, (US$ Billion)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018- 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Revive Therapeutics Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Faraday Pharmaceuticals
  • Abiomed
  • Omeros Corporation
  • Pharming Group N.V.
  • Nyken B.V.
  • Orexo AB
  • Opsona Therapeutics Limited
  • PledPharma AB
  • Prothix BV
  • Proteo, Inc.
  • Amyndas Pharmaceuticals LLC
  • Prolong Pharmaceuticals
  • Stealth BioTherapeutics Inc.
  • Zealand Pharma A/S
  • Antipodean Pharmaceuticals, Inc.
  • Bayer AG
  • Angion Biomedica Corp.
  • Bolder Biotechnology, Inc.
  • Curatis Pharma GmbH
  • Biomedica Management Corporation
  • Ensemble Therapeutics Corporation
  • Gilead Sciences, Inc.
  • Erimos Pharmaceuticals, LLC.

10. Section

  • Research Methodology
  • About Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦